Nutrishus Brands, Inc. – 612938 – 07/28/2021

2024 First Generic Drug Approvals

The FDA works with many people and groups, such as patients, caregivers, and drug and device manufactures, to support rare disease product development.

The Rare Diseases Program facilitates, supports and accelerates the development of drug and biologic products for the benefit of patients with rare disorders

Information on FDA-approved drugs released for sale on the market, such as dosage, side effects, and disposal methods

Abdallah Candies is voluntarily recalling a specific lot of Pecan Caramel Clusters, due to a mislabeled allergen. Product contains Cashews that were not listed on the product label. Product was sold and distributed exclusively to Lunds & Byerlys, as a private label, sold in the state of Minnesota.

The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatric